Author

C. S. Foo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:mouse· 5 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 3 Research Focus:benchmarking· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. Neyts· 5 shared R. Abdelnabi· 5 shared B. Weynand· 4 shared D. Jochmans· 4 shared L. Vangeel· 4 shared K. Dallmeier· 3 shared S. De Jonghe· 3 shared A. K. Chatterjee· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

J. Neyts

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection

R. Abdelnabi, C. S. Foo, S. Kaptein, R. Boudewijns, L. Vangeel, S. De Jonghe, D. Jochmans, B. Weynand, J. Neyts

This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.

bioRxiv · May 13, 2022Microbiology

Updated vaccine protects from infection with SARS-CoV-2 variants, prevents transmission and is immunogenic against Omicron in hamsters

S. Sharma, T. Vercruysse, L. Sanchez-Felipe, W. Kerstens, P. Maes, R. Abdelnabi, C. S. Foo, V. Lemmens, D. Van Looveren, G. Baele, B. Weynand, P. Lemey, J. Neyts, H. J. Thibaut, K. Dallmeier

This study shows an updated vaccine candidate provides full protection against multiple SARS-CoV-2 variants, prevents transmission, and induces neutralizing antibodies against Omicron in hamsters.

bioRxiv · Nov 12, 2021 · PreprintMicrobiology

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

K. Vandyck, R. Abdelnabi, K. Gupta, D. Jochmans, A. Jekle, J. Deval, D. Misner, D. Bardiot, C. S. Foo, C. Liu, S. Ren, L. Beigelman, L. M. Blatt, S. Boland, L. Vangeel, , J. Neyts

This study evaluates ALG-097111, a selective SARS-CoV-2 3CLpro inhibitor, showing potent in vitro activity and significant in vivo antiviral effects in Syrian hamsters.

bioRxiv · Feb 14, 2021Microbiology

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

C. S. Foo, R. Abdelnabi, S. J. F. Kaptein, X. Zhang, S. ter Horst, R. Mols, L. Delang, J. Rocha-Pereira, L. Coelmont, P. Leyssen, K. Dallmeier, V. Vergote, E. Heylen, L. Vangeel, A. K. Chatterjee, , J. Neyts

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

bioRxiv · Feb 1, 2021 · PreprintMicrobiology

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

R. Abdelnabi, C. S. Foo, S. J. F. Kaptein, X. Zhang, L. Langendries, L. Vangeel, J. Breuer, J. Pang, R. Williams, V. Vergote, E. Heylen, P. Leyssen, K. Dallmeier, L. Coelmont, D. Jochmans, , J. Neyts

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

bioRxiv · Dec 10, 2020Microbiology